ClinicalTrials.gg
Not yet recruitingNCT07716241Updated Jul 21, 2026

A Phase I Study of Single and Multiple Doses of HS-20136-2 Injection in Healthy or Obese Participants

A Phase 1 interventional study of HS-20136-2 and Placebo in Obesity, sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-21.

Sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd. (part of Hansoh Pharmaceutical Group Company Limited) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
92
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 600 studies in Obesity with a site in China — 221 open to participants now, 282 under way, 67 of them phase 3. Obesity · China.

Planned enrollment
302nd of 502
92 · median 120
Started
2026
with 133 others
Phase 1
93 of 600
29 open now
Primary completion
2027-05
later than 164 of 280 live
Registered
525th of 600
by date

Among the 600 studies in Obesity with a site in China, this one is the 302nd largest by planned enrollment of the 502 interventional ones that give a count, is one of 134 that started in 2026, is one of 93 in phase 1, reaches primary completion later than 164 of the 280 other live ones, and was the 525th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

221 of the 600 studies in Obesity with a site in China are open now. Recruiting first, the newest first:

216 more — sign in →

All 221 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 600 studies in Obesity with a site in China, or all of them as a file.
02

Study summary

The study is being conducted to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of HS-20136-2 injection in healthy/obese participants.

Read the detailed description

A Single-Center, Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Subcutaneous Administration of HS-20136-2 Injection in Healthy/Obese Participants

03

Conditions studied

  • Obesity

Browse trials for

Keywords

  • obesity
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged between 18 and 55 years (inclusive) at screening, male or female.
  2. Participants must fully understand the study content, procedures, and potential adverse reactions, and voluntarily sign the form (ICF) prior to any study-related procedures.
  3. Agree to use effective measures and refrain from sperm or egg donation from the time of signing the ICF until 4 months after the last dose.
  4. Agree to abstain from alcohol, smoking, and food or beverages containing xanthine or caffeine (including chocolate, tea, coffee, cola, etc.), and refrain from strenuous exercise from 48 hours prior to dosing until discharge from the study site.
  5. Self-reported body weight fluctuation of ≤ 5.0% within 12 weeks prior to screening through diet and exercise control alone.
  6. Willing and able to maintain a stable diet and exercise lifestyle throughout the study period.
  7. SAD cohort: body weight ≥ 50 kg, 19.0-28.0 kg/m² (inclusive). MAD cohort: BMI 28.0-40.0 kg/m² (inclusive).

Exclusion criteria

Exclusion Criteria:

  1. History of cardiovascular, respiratory, hepatic, renal, gastrointestinal, psychiatric, neurological, hematological, immunological, or metabolic disorders (e.g., recurrent hypoglycemia of unknown cause) that, in the investigator's opinion, would make the participant unsuitable for participation in this study.
  2. abnormalities in vital signs, physical examination, laboratory tests, or 12-lead (ECG) at screening, as judged by the investigator.
  3. Presence of diseases that, in the investigator's judgment, may significantly affect drug or nutrient absorption, including clinically significant gastrointestinal disorders (e.g., active inflammatory bowel disease) or symptoms of gastrointestinal disturbance; or any condition that may affect drug absorption, such as subtotal or total gastrectomy, sleeve gastrectomy, gastric bypass surgery, or resection of any intestinal segment.
  4. Diagnosis of chronic pancreatitis or history of idiopathic acute pancreatitis, or serum amylase or lipase above the (ULN) at screening. Participants with a history of acute pancreatitis due to cholelithiasis may be enrolled if they have undergone cholecystectomy.
  5. History of acute cholecystitis, or presence of symptomatic/stone-related cholelithiasis requiring treatment on prior or screening ultrasound (except for participants who have undergone cholecystectomy and are deemed eligible by the investigator).
  6. Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN-2), or screening calcitonin level ≥ 50 ng/L.
  7. Participation in any other clinical trial of a drug or medical device within 3 months prior to screening (excluding those who did not receive the product or device).
  8. History of diabetes mellitus (type 1, type 2, or rare forms of diabetes).
  9. Presence of endocrine disorders or history thereof that may significantly affect body weight (e.g., Cushing's syndrome, hypothyroidism, or hyperthyroidism; except for hypothyroidism managed with a stable thyroid hormone replacement regimen for at least 6 months), or obesity due to single-gene mutations or hereditary obesity syndromes.
  10. Use of any medication or treatment known to cause significant weight gain or weight loss within 3 months prior to screening.
  11. Any other condition that, in the investigator's opinion, would make the participant unsuitable for enrollment in this study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
92 participants (estimated)

Study arms

  • Experimental
    HS-20136-2

    Subcutaneous injection once,Subcutaneous injection three times

    Drug: HS-20136-2

  • Placebo comparator
    placebo

    Subcutaneous injection once,Subcutaneous injection three times

    Drug: Placebo

Interventions

  • DrugHS-20136-2

    Single-dose pen of HS-20136-2 injection solution

  • DrugPlacebo

    Single-dose of placebo

  • DrugHS-20136-2

    multi-dose pen of HS-20136-2 injection solution

  • Drugplacebo

    multi-dose of placebo

06

What researchers measure

Primary outcomes

  1. Number of Adverse Events

    A summary of adverse events, including Serious Adverse Events(SAEs)

    Time frame: Start of Treatment to end of study (approximately 57 days or 112 days)

Secondary outcomes

  1. Area under the plasma concentration-time curve (AUC) of HS-20136-2

    AUC of HS-20136-2 after single subcutaneous injection

    Time frame: Start of Treatment to end of study (approximately 57 days)

  2. AUC of HS-20136-2

    AUC of HS-20136-2 after multiple subcutaneous injection

    Time frame: Start of Treatment to end of study (approximately 112 days)

  3. Immunogenicity

    anti- HS-20136-2 antibody

    Time frame: Start of Treatment to end of study (approximately 112 days)

  4. body weight change

    body weight change from baseline

    Time frame: Start of Treatment to end of study (approximately 112 days)

07

Study locations

1 site
  • The Second Hospital of Ahui Medical University
    Hefei, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for May 2027, 7 months later.

Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 7 months is below that.

Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2026
First posted
Jul 21, 2026
StartEst.
Sep 22, 2026
Primary completionEst.
May 14, 2027
CompletionEst.
May 14, 2027
Last update
Jul 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07716241
Responsible party
Sponsor
First posted
Jul 21, 2026
Start date
Sep 22, 2026 (estimated)
Primary completion
May 14, 2027 (estimated)
Completion
May 14, 2027 (estimated)
Last update
Jul 21, 2026

Study contacts

Wei Hu
Contact
huwei@ahmu.edu.com
13856086475
Renpeng Zhou
Contact
zhourenpeng@ahmu.edu.cn
15956933545

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion